Showing 2601-2610 of 5646 results for "".
- Novartis Provides Update On Use and Safety of Beovu (brolucizumab)https://modernod.com/news/novartis-provides-update-on-use-and-safety-of-beovu-brolucizumab/2477873/An internal review of post-marketing safety case reports of brolucizumab (Beovu; Novartis) has confirmed a rare occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion. Following FDA approval of Beovu in October 2019, Novartis rece
- AbbVie Enters Deal to Develop Antibody Therapeutic for COVID-19https://modernod.com/news/abbvie-enters-deal-to-develop-antibody-therapeutic-for-covid-19/2477869/AbbVie entered into a collaboration with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop an antibody therapeutic to prevent and treat COVID-19, the parties announced Friday. The fully human, neutralising antibody 47D11, which targets the conserved domain of the spike pro
- Diabetic Retinopathy Appears Linked to Depressionhttps://modernod.com/news/diabetic-retinopathy-appears-linked-to-depression/2477864/People with diabetic retinopathy experience depression at higher rates than the general population, but the rate decreases at the most severe stage of the disease, an analysis of a large database shows, according to a Medscape report.
- AstraZeneca Targeting Over 2 Billion COVID-19 Vaccine Doses After Latest Dealshttps://modernod.com/news/astrazeneca-targeting-over-2-billion-covid-19-vaccine-doses-after-latest-deals/2477865/AstraZeneca said it signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII) in a move aimed at broadening global access to an experimental COVID-19 vaccine being developed at the University of Oxford. The
- Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screeninghttps://modernod.com/news/devlyn-optical-partnering-with-eyenuk-to-offer-diabetic-retinopathy-screening/2477858/Eyenuk and Devlyn Optical, an optical retailer with over 1,000 stores in Mexico, Guatemala, El Salvador, and the US, announced that they will collaborate to pilot diabetic retinopathy (DR) screening services at Devlyn
- AAO Statement on Death of George Floyd and Its Aftermathhttps://modernod.com/news/aao-statement-on-death-of-george-floyd-and-its-aftermath/2477850/The American Academy of Ophthalmology (AAO) released a statement on Monday regarding the death of George Floyd and its aftermath. The statement reads: “The American Academy of Ophthalmology deplores the senseless death of George Floyd and others under similar circumstances. We
- Nearly Half Of Americans Delayed Medical Care Due To Pandemichttps://modernod.com/news/nearly-half-of-americans-delayed-medical-care-due-to-pandemic/2477828/As the coronavirus threat ramped up in March, hospitals, health systems and private practices dramatically reduced inpatient, nonemergency services to prepare for an influx of COVID-19 patients, according to a Kaiser Health News
- Port Delivery System With Ranibizumab Shows Positive Phase 3 Results in Wet AMDhttps://modernod.com/news/port-delivery-system-with-ranibizumab-shows-positive-phase-3-results-in-wet-amd/2477824/Genentech announced positive topline results from the phase 3 Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with wet age-related macular degeneration (AMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continu
- Novavax Initiates Phase 1/2 Trial of COVID-19 Vaccine Candidate NVX‑CoV2373https://modernod.com/news/novavax-initiates-phase-1-2-trial-of-covid-19-caccine-candidate-nvxe28091cov2373/2477822/Novavax on Monday announced that it has enrolled the first participants in a phase 1/2 trial of its coronavirus vaccine candidate NVX‑CoV2373, with preliminary results expected in July. The news follows the Coalition for Epidemic Preparedness Innovations (CEPI) recently awarding up to
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus